阿斯利康(AZN.US)BTK抑制剂新适应症获欧盟批准用于治疗套细胞淋巴瘤

智通财经网2025-05-06

当地时间5月6日，阿斯利康(AZN.US)宣布，阿可替尼与苯达莫司汀和利妥昔单抗联合使用已在欧盟获得批准，用于治疗未接受过治疗且不适合接受自体干细胞移植的套细胞淋巴瘤(MCL)成年患者。新闻稿指出，这是欧盟首个也是唯一一个获批用于该适应症的BTK抑制剂。截图来源：企业官网此项批准是基于 III 期临床试验 ECHO 的积极结果。这是一项随机、双盲、安慰剂对照、多中心 III 期临床试验，旨在评估...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533752907?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-06 14:52","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2533752907","market":"hk","top_or_hot":-1,"title":"阿斯利康(AZN.US)BTK抑制剂新适应症获欧盟批准 用于治疗套细胞淋巴瘤","media":"智通财经网","content":"<div>\n<p>当地时间5月6日，阿斯利康(AZN.US)宣布，阿可替尼与苯达莫司汀和利妥昔单抗联合使用已在欧盟获得批准，用于治疗未接受过治疗且不适合接受自体干细胞移植的套细胞淋巴瘤(MCL)成年患者。新闻稿指出，这是欧盟首个也是唯一一个获批用于该适应症的BTK抑制剂。截图来源：企业官网此项批准是基于 III 期临床试验 ECHO 的积极结果。这是一项随机、双盲、安慰剂对照、多中心 III 期临床试验，旨在评估...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrenz0681593.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康(AZN.US)BTK抑制剂新适应症获欧盟批准 用于治疗套细胞淋巴瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康(AZN.US)BTK抑制剂新适应症获欧盟批准 用于治疗套细胞淋巴瘤\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-06 14:52 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrenz0681593.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>当地时间5月6日，阿斯利康(AZN.US)宣布，阿可替尼与苯达莫司汀和利妥昔单抗联合使用已在欧盟获得批准，用于治疗未接受过治疗且不适合接受自体干细胞移植的套细胞淋巴瘤(MCL)成年患者。新闻稿指出，这是欧盟首个也是唯一一个获批用于该适应症的BTK抑制剂。截图来源：企业官网此项批准是基于 III 期临床试验 ECHO 的积极结果。这是一项随机、双盲、安慰剂对照、多中心 III 期临床试验，旨在评估...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrenz0681593.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrenz0681593.shtml","article_id":"2533752907","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533752907","pubTimestamp":1746514320,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"当地时间5月6日，阿斯利康宣布，阿可替尼与苯达莫司汀和利妥昔单抗联合使用已在欧盟获得批准，用于治疗未接受过治疗且不适合接受自体干细胞移植的套细胞淋巴瘤成年患者。新闻稿指出，这是欧盟首个也是唯一一个获批用于该适应症的BTK抑制剂。接受阿可替尼联合治疗的患者的中位无进展生存期  为 66.4 个月， 而单独接受化疗免疫疗法的患者的中位 PFS 为 49.6 个月。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AZN":"阿斯利康","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4007":"制药","BK4568":"美国抗疫概念"},"translate_title":"AstraZeneca (AZN.US) BTK inhibitor new indication approved by the EU for the treatment of mantle cell lymphoma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"当地时间5月6日，阿斯利康(AZN.US)宣布，阿可替尼与苯达莫司汀和利妥昔单抗联合使用已在欧盟获得批准，用于治疗未接受过治疗且不适合接受自体干细胞移植的套细胞淋巴瘤(MCL)成年患者。新闻稿指出，这是欧盟首个也是唯一一个获批用于该适应症的BTK抑制剂。截图来源：企业官网此项批准是基于 III 期临床试验 ECHO 的积极结果。这是一项随机、双盲、安慰剂对照、多中心 III 期临床试验，旨在评估阿可替尼联合苯达莫司汀和利妥昔单抗治疗的疗效和安全性，并与 SoC 化学免疫疗法(苯达莫司汀和利妥昔单抗)进行比较，用于治疗 65 岁及以上、既往未接受过治疗的 MCL 成年患者。主要终点是 PFS。该试验表明，与标准化疗免疫疗法相比， 阿可替尼联合苯达莫司汀和利妥昔单抗疗法可将疾病进展或死亡风险降低 27%(HR=0.73)。接受阿可替尼联合治疗的患者的中位无进展生存期 (PFS) 为 66.4 个月， 而单独接受化疗免疫疗法的患者的中位 PFS 为 49.6 个月。\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533752907","isCrawlerRequest":true}

阿斯利康(AZN.US)BTK抑制剂新适应症获欧盟批准 用于治疗套细胞淋巴瘤

精彩评论

阿斯利康(AZN.US)BTK抑制剂新适应症获欧盟批准用于治疗套细胞淋巴瘤